Following the results of a recent study which showed that Eli Lilly’s sepsis drug, Xigris, provided no better results in reducing mortality than that of a placebo, the pharmaceutical company announced it will pull the product from the market worldwide.
Both The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have acknowledged that the drug’s manufacturer has informed them of the decision to pull activated drotrecogin alfa, otherwise known as Xigris, from pharmacy shelves.
Xigris is used to treat severe cases of sepsis in high-risk patients, but the drug’s efficacy has been questioned since it was authorized for use almost 10 years ago.
